ERBB2 and breast carcinoma: Unlike trastuzumab that, as described in the literature, had no effect against MCF-7 tumors, HER2bsFab induced a significant slowdown of tumor growth suggesting that HER2bsFab could provide a clinical benefit in the case of both high- and low-HER2-overexpressing breast cancers.